WINT READ THE FULL WINT RESEARCH REPORT Multiple Programs Focus on Unmet Needs In Cardiogenic Shock & AHF Pennsylvania-based Windtree Therapeutics, Inc. (NASDAQ:WINT) is a biopharmaceutical company ...
To position istaroxime for Phase 3 readiness, WINT launched the small Phase 2 study in SCAI Stage C. SCAI Stage C cardiogenic shock is a more severely ill patient population than the participants ...
In addition to the American College of Cardiology and the American Heart Association, the guideline was written in ...
Cardiogenic shock, a life-threatening condition in which ... and the Society for Cardiovascular Angiography and Interventions (SCAI). Additional Resources: After Feb. 27, 2025, view the manuscript ...
The SHOCK study (SHould we emergently revascularize ... Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of ...
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by ...
Transferred patients had worse Cardiogenic Shock Working Group–modified Society for Cardiovascular Angiography and Interventions (CSWG‐SCAI) shock stage and a greater number of vasoactive medications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback